Literature DB >> 34183115

Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease.

Omar S Usmani1, Rajiv Dhand2, Federico Lavorini3, David Price4.   

Abstract

For more than 50 years, small airways disease has been considered a key feature of chronic obstructive pulmonary disease (COPD) and a major cause of airway obstruction. Both preventable and treatable, small airways disease has important clinical consequences if left unchecked. Small airways disease is associated with poor spirometry results, increased lung hyperinflation, and poor health status, making the small airways an important treatment target in COPD. The early detection of small airways disease remains the key barrier; if detected early, treatments designed to target small airways may help reduce symptoms and allow patients to maintain their activities. Studies are needed to evaluate the possible role of new drugs and novel drug formulations, inhalers, and inhalation devices for treating small airways disease. These developments will help to improve our management of small airways disease in patients with COPD.
Copyright © 2021 [Author/Employing Institution]. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34183115     DOI: 10.1016/j.mayocp.2021.03.016

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  2 in total

1.  Impact of Personal, Subhourly Exposure to Ultrafine Particles on Respiratory Health in Adolescents with Asthma.

Authors:  Ashley L Turner; Cole Brokamp; Chris Wolfe; Tiina Reponen; Patrick H Ryan
Journal:  Ann Am Thorac Soc       Date:  2022-09

Review 2.  Impulse Oscillometry, Small Airways Disease, and Extra-Fine Formulations in Asthma and Chronic Obstructive Pulmonary Disease: Windows for New Opportunities.

Authors:  Alfredo Chetta; Nicola Facciolongo; Cosimo Franco; Laura Franzini; Alessio Piraino; Carmelina Rossi
Journal:  Ther Clin Risk Manag       Date:  2022-10-01       Impact factor: 2.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.